MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway

Sun,Wei; Ma,Yiping; Chen,Peng; Wang,Dong

doi:10.3892/mmr.2015.3181

MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway

Authors:
- Wei Sun
- Yiping Ma
- Peng Chen
- Dong Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300051, P.R. China, Department of Pharmacy, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China, Department of Thoracic Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China
Published online on: January 12, 2015 https://doi.org/10.3892/mmr.2015.3181
Pages: 3854-3859

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the primary causes of mortality worldwide and drug resistance is the key contributing factor which results in the failure of lung cancer chemotherapy. Previous studies have shown that microRNA (miR)‑10a was involved in the reversal of cisplatin (DDP) resistance in numerous types of tumors; however, the underlying mechanism of action of this remains to be fully elucidated. In the present study, miR‑10a silencing in human DDP‑resistant lung cancer A549/DDP cells was demonstrated to improve DDP sensitivity, apoptosis, intracellular rhodamine‑123 content as well as the expression and activity of caspase‑3/8. In addition, miR‑10a suppressed the cellular expression of P‑glycoprotein, multi‑drug resistance protein (MDR) 1, MDR‑associated protein 1, RhoE, B cell lymphoma‑2 and survivin in A549/DDP cells. Furthermore, miR‑10a silencing inhibited the secretion of transforming growth factor (TGF)‑β, phosphorylation of Sma‑ and Mad‑related protein (Smad)2, signal transducer and activator of transcription (STAT)3 and STAT5, the transcriptional activity of hypoxia‑inducible factor and eukaryotic translation initiation factor 4E in human lung cancer A549/DDP cell line. These results therefore indicated that miR‑10a may be a potential target for improving the effectiveness of lung cancer chemotherapy via regulation of the TGF‑β/Smad2/STAT3/STAT5 pathway.

View Figures

View References

1	Joshi P, Middleton J, Jeon YJ and Garofalo M: MicroRNAs in lung cancer. World J Methodol. 2:59722014.
2	Liu R, Liu X, Zheng Y, Gu J, Xiong S, Jiang P, Jiang X, Huang E, Yang Y, Ge D and Chu Y: MicroRNA7 sensitizes nonsmall cell lung cancer cells to paclitaxel. Oncol Lett. 5:219322002014.
3	Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, Zhu X, Chen B, Wu J and Li M: miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 73:5402–5415. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ayaz L, Görür A, Yaroğlu HY, Ozcan C and Tamer L: Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 139:1499–1506. 2013. View Article : Google Scholar : PubMed/NCBI
5	Köhler CU, Bryk O, Meier S, Lang K, Rozynek P, Brüning T and Käfferlein HU: Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochem Biophys Res Commun. 438:48–53. 2013. View Article : Google Scholar : PubMed/NCBI
6	Zhu Y, Liu XJ, Yang P, Zhao M, Lv LX, Zhang GD, Wang Q and Zhang L: Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines. Asian Pac J Cancer Prev. 7:321932262014.
7	Ulasli SS, Celik S, Gunay E, Ozdemir M, Hazman O, Ozyurek A, Koyuncu T and Unlu M: Anticancer Effects of Thymoquinone, Caffeic Acid Phenethyl Ester and Resveratrol on A549 Non-small Cell Lung Cancer Cells Exposed to Benzo(a)pyrene. Asian Pac J Cancer Prev. 14:6159–6164. 2013. View Article : Google Scholar : PubMed/NCBI
8	Sun PL, Jin Y, Kim H, Seo AN, Jheon S, Lee CT and Chung JH: Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch. 463:427–436. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhang C, Zhou F, Li N, Shi S, Feng X, Chen Z, Hang J, Qiu B, Li B, Chang S, et al: Overexpression of RhoE has a prognostic value in non-small cell lung cancer. Ann Surg Oncol. 14:2628–2635. 2007. View Article : Google Scholar : PubMed/NCBI
10	Prochazka L, Koudelka S, Dong LF, Stursa J, Goodwin J, Neca J, Slavik J, Ciganek M, Masek J, Kluckova K, et al: Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α-tocopheryl succinate. Apoptosis. 18:286–299. 2013. View Article : Google Scholar : PubMed/NCBI
11	Minami T, Kijima T, Otani Y, Kohmo S, Takahashi R, Nagatomo I, Hirata H, Suzuki M, Inoue K, Takeda Y, et al: HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. Mol Cancer Ther. 11:830–841. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wang YS, Miao LY, Liu L, Cai HR, Ding JJ, Ren SX, Zhou CC and Schmid-Bindert G: Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment. Chin Med J (Engl). 126:3931–3935. 2013.
13	Cha Y, Kim DK, Hyun J, Kim SJ and Park KS: A3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells. Cell Signal. 25:1245–1251. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhang K, Zhang Y, Liu C, Xiong Y and Zhang J: MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential. Int J Oncol. 3:9509582014.
15	Li Y, Li L, Guan Y, Liu X, Meng Q and Guo Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun. 440:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
16	Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW and Winn RA: Heterotrimeric g-protein, gα16, is a critical downstream effector of non-canonical wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer. PLoS One. 8:e768952013. View Article : Google Scholar
17	Surowiak P, Pawełczyk K, Maciejczyk A, Pudełko M, Kołodziej J, Zabel M, Murawa D, Drag M, Gansukh T, Dietel M and Lage H: Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res. 28(5B): 2967–2974. 2008.PubMed/NCBI
18	Ak Y, Demirel G and Gülbas Z: MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy. Nucl Med Commun. 28:541–546. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wang L, Deng Q, Wang J, Bai X, Xiao X, Lv HR, Zhao MF and Liu PJ: Effect of CIK on multidrugresistance reversal and increasing the sensitivity of ADR in K562/ADR cells. Oncol Lett. 4:177817822014.
20	Kin R, Kato S, Kaneto N, Sakurai H, Hayakawa Y, Li F, Tanaka K, Saiki I and Yokoyama S: Procyanidin C1 from Cinnamomi Cortex inhibits TGF-β-induced epithelial-to-mesenchymal transition in the A549 lung cancer cell line. Int J Oncol. 43:1901–1906. 2013.PubMed/NCBI
21	Tu B, Peng ZX, Fan QM, Du L, Yan W and Tang TT: Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway. Exp Cell Res. 320:164–173. 2014. View Article : Google Scholar